India unveils world's first nasal vaccine for Covid (Photo for representation)
The booster dose of Bharat Biotech’s Covid-19 nasal vaccine iNCOVACC was given emergency use authorisation (EUA) by the Drugs Controller General of India (DCGI).
The EUA is reported to have been granted for restricted emergency use as the third dose for adults irrespective of having been administered Covaxin or Covishield vaccine doses.
According to the Hyderabad-based vaccine manufacturer, the nasal route has excellent potential for vaccination due to the organised immune systems of the nasal mucosa.
iNCOVACC is India’s first nasal vaccine developed against Covid-19. The nasal vaccine can be taken after six months of the second dose. As this is non-invasive and needle-free, it becomes easy to administer.
The intranasal immunisation of ChAd-SARS-CoV-2-S can create an immune response in the nose, which is the point of entry for the virus. The booster dose will thereby protect against disease, infection, and transmission.
US President Donald Trump has asked Israeli Prime Minister Benjamin Netanyahu to end the war…
Union Home Minister Amit Shah on Thursday highlighted the achievements of the central government's digital…
The US State and Defence Departments have begun moving non-essential personnel out of several locations…
Srinivas Mukkamala was elected President of the American Medical Association, the first person of Indian…
External Affairs Minister S Jaishankar while speaking at GMF Brussels Forum 2025 said that there…
Foreign Secretary Vikram Misri paid a visit to Abu Dhabi, UAE on June 10. His…